Investigating the effects of methylphenidate and atomoxetine on emotional intelligence, excutive function and self-efficacy of 12-18-year-old adolescents withThe effect of methylphenidate and automoxetine on emotional intelligence, executive function and self-efficacy of adolescents aged 12 to 18 years with Attention Deficit Hyperactivity Disorder (ADHD)

Investigating the effects of methylphenidate and atomoxetine on emotional intelligence, excutive function and self-efficacy of 12-18-year-old adolescents with ADHD

In a clinical trial, a parallel-group, double-blinded, randomized, and placebo-controlled study is conducted on 76 patients. These patients are randomly assigned to either the intervention group or the control group using a block randomization method.

This clinical trial is being carried out on patients diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD) at Farshchian Hospital in Hamedan. The outcome assessor will remain unaware of the patient’s treatment type (drug therapy), ensuring that the study is single-blinded.

Inclusion criteria: Consent to participation in the study by parents;Ages 12 to 18 years;Suffering from Attention Deficit Hyperactivity Disorder (ADHD) Exclusion criteria :The existence of a range of psychotic disorders;Autism Spectrum disorders;Severe physical illnesses;intellectual disability

In a group, Ritalin (manufactured by Karan Pharmaceutical Company, Iran) is initially prescribed at a dose of three-tenths of a milligram per kilogram of body weight per day. Subsequently, the medication dosage is increased up to 1 milligram per kilogram of body weight based on individual needs. The treatment duration is 12 weeks. In another group, Automecstin, manufactured by Tehran Darou Pharmaceutical Company in Iran, is initially prescribed at a dose of 40 milligrams per day for up to three days, and then gradually increased to 80 milligrams.

Investigating emotional intelligence, executive function and self-efficacy before and after the intervention.

The patients will be randomly assigned to intervention and control groups using block randomization. For this purpose, we will prepare four sheets of paper, writing on two sheets the name of the intervention and on the other two sheets the name of the control. The paper sheets will be pooled, placed in a container, and randomly drawn one at a time for each patient without replacement until all four sheets are drawn. The four paper sheets will be then placed back into the container, and this action repeated until the sample size is reached.

The person evaluating the outcomes is unaware of patient allocation to intervention or control groups; therefore, the study is conducted as a single-blind trial.

No - There is not a plan to make this available